Healthcare Industry News: colorectal cancer
News Release - July 17, 2007
Aventir Biotech Launches New 510(k) Cleared Fecal Occult Blood Screen TestCARLSBAD, CA--(Healthcare Sales & Marketing Network)--Jul 17, 2007 -- Aventir Biotech's ForSureŽ Fecal Occult Blood (FOB) Screen Card Test has just been cleared for both over-the-counter and professional applications by the FDA, making it readily available for convenient and hygienic detection of possible Colorectal Carcinoma, Crohn's Disease, Ulcerative Colitis, and Colon Polyps in humans. colorectal cancer is the second leading cause of cancer-related death for men and women.
Aventir's innovative product will meet the growing needs of improved sample collection and testing accuracy for diseases related to Colorectal Carcinoma. "We are very pleased to bring the ForSureŽ Fecal Occult Blood (FOB) Screen Card Test, the first licensed OTC product to the US market. Early detection of the disease will help dramatically reduce healthcare costs across the nation," stated Jerry Lee, Marketing Director of Aventir Biotech, LLC.
This screen card test can accurately identify indicators of hHb (human hemoglobin) in stool. ForSureŽ Fecal Occult Blood (FOB) Screen Card Test is stable without the use of any dietary restrictions. These factors make this test a more effective option than the traditional guaiac-based tests. The ForSureŽ test features a dual-purpose collection tube to serve as a sample applicator and a device to preserve the transportation of patient specimen collection. The test has been designated as CLIA-waived, and will provide its user with a clear and easy way to diagnose Colorectal Carcinoma in just minutes.
Aventir Biotech LLC. is an FDA-registered company located in Carlsbad, CA, specializing in the development and manufacturing of in-vitro diagnostic devices for the detection of drugs of abuse, fertility hormones, cancer markers, infectious diseases and glucose. Aventir proudly offers high-quality, cost-effective products for point-of-care needs worldwide.
Please visit www.aventirbio.com for additional information.
Source: Aventir Biotech
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.